Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LJPC-501 in pediatric catecholamine-resistant hypotension associated with distributive shock
2017-005153-37Phase 2Completed
- Sponsor
- La Jolla Pharmaceutical Company
- Start
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of Angiotensin II in Catecholamine-resistant hypotension, Vasoplegia, sponsored by La Jolla Pharmaceutical Company. Started Mar 2018; status: completed.
02
Drugs
Angiotensin II
03
Conditions
Catecholamine-resistant hypotensionVasoplegia
Beyond the preview
Go deeper on 2017-005153-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005153-37.